DIASENSE

Denmark · owned by Independent (Denmark) · diasense.dk · 20 vendors

DIASENSE develops Quantum Diamond Magnetic Microscopes for semiconductor chip failure analysis and production monitoring. Their cutting-edge quantum sensing technology enables contactless, high-resolution analysis of integrated circuits to detect failure mechanisms invisible to traditional techniques.

Resilience scores

Disruption prediction

DIASENSE has an estimated 17% probability of disruption in the next 6 months.

7 of DIASENSE's 20 vendors monitored for disruptions.

Technology vendors

Insights

Last updated 2026-09-13 · revision 15

20 direct vendors, 188 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 5/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

The company shows moderate migration readiness. The primary challenge is the nature of their business: as a provider of physical 'Quantum Diamond Magnetic Microscopes,' core operations are hardware-tethered and cannot be fully digitized or migrated to the cloud. However, the IT and data analysis components appear highly portable. The detection of 57 external services implies a cloud-native or SaaS-heavy architecture, which is significantly easier to migrate than monolithic on-premise software. The geographic diversity of these services (7 countries) suggests low vendor lock-in to a single provider ecosystem. Conversely, strict GDPR compliance requires data residency within the EU, limiting hosting options. Additionally, the lack of revenue (€0) limits the financial resources available to execute complex migration projects.

Compliance

3 in-scope frameworks identified; showing 3.

GDPR (source) — Assessment Required

As a Danish company with employees, customers, and business operations, DIASENSE processes personal data (employee records, customer contacts, supplier information) within the EU.

GDPR applies to all EU-based companies processing personal data. Non-compliance can result in fines up to 4% of annual turnover or €20M. High risk due to mandatory applicability and severe penalties.

SOC 2 (source) — Assessment Required

Relevant if DIASENSE provides data analysis services or cloud-based monitoring that handles customer data.

SOC2 is relevant for technology service providers. While DIASENSE focuses on hardware, any data analysis services or cloud-based monitoring could benefit from SOC2 for customer trust and B2B relationships.

ISO 27001 (source) — Assessment Required

Highly relevant for technology companies handling sensitive IP and customer data in the semiconductor industry.

ISO 27001 is expected by enterprise customers and partners in the semiconductor industry where IP protection is critical. Medium risk as it affects competitive positioning and customer trust.

Financials

Three-year financials

Financial Resilience Score: 6/10

DIASENSE ApS demonstrates moderate resilience underpinned by strong institutional backing and proprietary intellectual property. Securing a €2.5 million seed round from Vækstfonden and Pre-Seed Ventures provides a significant financial runway and validates the commercial potential of its SU-8 based biosensor technology. The company's lean operational structure and focus on a high-growth market like point-of-care diagnostics further enhance its foundational stability during the pre-commercial phase. However, the company faces substantial risks typical of early-stage MedTech ventures, primarily its total dependency on external funding and lack of revenue. The path to commercialization is contingent upon navigating complex regulatory hurdles, such as CE marking under IVDR, and achieving successful clinical validation. Any delays in these processes or failure to secure a subsequent Series A funding round could critically impact the company's ability to sustain operations.

Key strengths: Strong Investor Backing (Vækstfonden, Pre-Seed Ventures), Proprietary Patented SU-8 Biosensor Technology, Large Addressable Point-of-Care Market, Lean Operational Structure

Risk factors: Total Revenue Dependency on Cash Reserves, Stringent Regulatory Approval Hurdles (CE Mark/FDA), Market Adoption and Competition Risk, Requirement for Future Series A Funding

Revenue by geography

Revenue by product/service

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report